Tissue factor expression in obese type 2 diabetic subjects and its regulation by antidiabetic agents.
Tissue factor expression in obese type 2 diabetic subjects and its regulation by antidiabetic agents.
复制标题
DOI：
10.1155/2015/291209
复制
发表时间：
2015
影响因子：
3.3
通讯作者：
Samad F
中科院分区：
文献类型：
--
作者：
Wang J;Ciaraldi TP;Samad F
Objective.凝血激活增加可能导致肥胖和2型糖尿病（T2D）受试者中观察到的心血管并发症的高发生率。虽然组织因子（TF），凝血的主要起始物在肥胖中增加，但其在脂肪组织中的表达及其与代谢参数的关系尚不清楚。我们试图比较TF表达在血浆和脂肪组织的肥胖受试者和不T2D，其与代谢参数的相关性，并响应于抗糖尿病药物的调节。方法从糖尿病门诊招募受试者，通过下腹部皮下脂肪组织穿刺活检获得脂肪组织。在干预研究中，受试者被随机分为罗格列酮或二甲双胍治疗组，持续4个月。结果与肥胖非糖尿病患者相比，肥胖T2D患者的血浆TF抗原、活性和脂肪TF mRNA更高。血浆TF活性与空腹胰岛素、血糖和游离脂肪酸（FFA）相关，脂肪TF mRNA与血浆FFA相关。二甲双胍降低血浆TF活性，罗格列酮升高血浆TF活性。结论.特定的糖尿病相关代谢参数，而不是肥胖本身，与TF表达相关。不同类型的抗糖尿病药物对TF活性的调节可能与保护性或不良心血管结局有关。
Objective. Increased coagulation activation may contribute to the high incidence of cardiovascular complications observed in obese and type 2 diabetes (T2D) subjects. Although tissue factor (TF), the primary initiator of coagulation is increased in obesity, its expression in adipose tissues and its association with metabolic parameters are unclear. We sought to compare TF expression in plasma and adipose tissues of obese subjects with and without T2D, its correlation with metabolic parameters, and regulation in response to antidiabetic drugs. Methods Subjects were recruited from diabetes clinics and adipose tissue was obtained by needle biopsy of lower subcutaneous abdominal depot. For the intervention study, subjects were randomized into treatment groups with rosiglitazone or metformin for 4 months. Results. Plasma TF antigen, activity, and adipose TF mRNA were greater in obese T2D subjects compared with obese nondiabetics. Plasma TF activity correlated with fasting insulin, glucose, and free fatty acids, (FFAs), and adipose TF mRNA correlated with plasma FFA. Plasma TF activity was reduced by metformin and increased with rosiglitazone treatment. Conclusions. Specific diabetes-related metabolic parameters, but not obesity per se, are correlated with TF expression. Regulation of TF activity by different classes of antidiabetic drugs may relate to protective or adverse cardiovascular outcomes.